plus therapeutics, inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and manufacture of treatments for cancer and other diseases. its lead product candidate is doceplus, a protein-stabilized pegylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. the company is also involved in developing doxoplus, a generic pegylated liposomal encapsulated doxorubicin to treat breast and ovarian cancer, multiple myeloma, and kaposi's sarcoma. it has a license agreement with nanotx, corp. to develop and commercialize nanotx's glioblastoma treatment. the company was formerly known as cytori therapeutics, inc. and changed its name to plus therapeutics, inc. in july 2019. plus therapeutics, inc. was founded in 1996 and is headquartered in austin, texas.
Company profile
Ticker
PSTV
Exchange
Website
CEO
Marc Hedrick
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CYTORI THERAPEUTICS, INC., MACROPORE INC
SEC CIK
Corporate docs
IRS number
330827593
PSTV stock data
Latest filings (excl ownership)
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
14 Mar 24
8-K
Regulation FD Disclosure
13 Mar 24
S-1/A
IPO registration (amended)
8 Mar 24
8-K
Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
5 Mar 24
10-K
2023 FY
Annual report
5 Mar 24
424B3
Prospectus supplement
22 Nov 23
S-1
IPO registration
22 Nov 23
EFFECT
Notice of effectiveness
21 Nov 23
8-K
Regulation FD Disclosure
20 Nov 23
CORRESP
Correspondence with SEC
17 Nov 23
Transcripts
PSTV
Earnings call transcript
2023 Q4
5 Mar 24
PSTV
Earnings call transcript
2023 Q3
31 Oct 23
PSTV
Earnings call transcript
2023 Q2
14 Aug 23
PSTV
Earnings call transcript
2023 Q1
20 Apr 23
PSTV
Earnings call transcript
2022 Q4
23 Feb 23
PSTV
Earnings call transcript
2022 Q3
21 Oct 22
PSTV
Earnings call transcript
2022 Q2
21 Jul 22
PSTV
Earnings call transcript
2022 Q1
22 Apr 22
PSTV
Earnings call transcript
2021 Q4
25 Feb 22
PSTV
Earnings call transcript
2021 Q3
22 Oct 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 11.01 mm | 11.01 mm | 11.01 mm | 11.01 mm | 11.01 mm | 11.01 mm |
Cash burn (monthly) | (no burn) | 771.67 k | 1.08 mm | 1.25 mm | 799.67 k | 1.10 mm |
Cash used (since last report) | n/a | 5.28 mm | 7.41 mm | 8.57 mm | 5.47 mm | 7.53 mm |
Cash remaining | n/a | 5.73 mm | 3.59 mm | 2.44 mm | 5.54 mm | 3.48 mm |
Runway (months of cash) | n/a | 7.4 | 3.3 | 1.9 | 6.9 | 3.2 |
Institutional ownership, Q2 2023
14.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 9 |
Opened positions | 0 |
Closed positions | 15 |
Increased positions | 0 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 206.20 mm |
Total shares | 632.46 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Intracoastal Capital | 300.00 k | $315.00 k |
NanoTx | 230.77 k | $466.00 k |
Vanguard | 72.86 k | $147.18 mm |
Geode Capital Management | 17.01 k | $34.35 mm |
BLK Blackrock | 6.96 k | $14.06 mm |
Tower Research Capital | 4.73 k | $9.56 mm |
Advisor | 133.00 | $268.00 k |
Group One Trading | 1.00 | $2.00 k |
Householder Group Estate & Retirement Specialist | 1.00 | $0.00 |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Feb 24 | Howard Clowes | Stock Option Common Stock | Grant | Acquire A | No | No | 2.03 | 2,250 | 4.57 k | 2,250 |
22 Feb 24 | Norman D. LaFrance | Stock Option Common Stock | Grant | Acquire A | No | No | 2.03 | 24,073 | 48.87 k | 24,073 |
22 Feb 24 | Hedrick Marc H | Stock Option Common Stock | Grant | Acquire A | No | No | 2.03 | 94,012 | 190.84 k | 94,012 |
22 Feb 24 | Andrew John Hugh MacIntyre Sims | Stock Option Common Stock | Grant | Acquire A | No | No | 2.03 | 18,933 | 38.43 k | 18,933 |
22 Feb 24 | Robert P Lenk | Stock Option Common Stock | Grant | Acquire A | No | No | 2.03 | 2,250 | 4.57 k | 2,250 |
News
Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defense
22 Apr 24
Plus Therapeutics Announces Validation & Clinical Implementation Of CSF-01 Leptomeningeal Cancer Cell Diagnostic
25 Mar 24
Recap: Plus Therapeutics Q4 Earnings
5 Mar 24
Plus Therapeutics Q4 EPS $(0.70) Beats $(1.07) Estimate, Sales $1.31M Beat $1.06M Estimate
5 Mar 24
Earnings Scheduled For March 5, 2024
5 Mar 24
Press releases
Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic
25 Mar 24
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases
11 Mar 24
Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
5 Mar 24